Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company")
announced financial results today for the fiscal second quarter
ended July 31, 2023.
"I am incredibly pleased and proud of our team’s accomplishments
in the second quarter of fiscal year 2024. We continued to deliver
excellent value for our clients and scale our business—all while
helping patients take a more active role in their healthcare and
achieve improved health outcomes," said CEO and Co-Founder Chaim
Indig.
Please visit the Phreesia investor relations website at
ir.phreesia.com to view the Company's Q2 Fiscal Year 2024
Stakeholder Letter.
Fiscal Second Quarter Ended July 31, 2023 Highlights
- Total revenue was $85.8 million in the quarter as compared to
$67.9 million in the same period in the prior year, an increase of
26%.
- Average number of healthcare services clients ("AHSCs") was
3,445 in the quarter as compared to 2,776 in the same period in the
prior year, an increase of 24%.
- Healthcare services revenue per AHSC remained relatively flat
at $18,268 in the quarter as compared to $18,248 in the same period
in the prior year. See "Key Metrics" below for additional
information.
- Total revenue per AHSC was $24,914 in the quarter as compared
to $24,448 in the same period in the prior year, an increase of 2%.
The increase was driven primarily by network solutions revenue
growth that outpaced AHSC growth. See "Key Metrics" below for
additional information.
- Net loss was $36.8 million in the quarter compared to $46.7
million in the same period in the prior year.
- Adjusted EBITDA was negative $11.5 million in the quarter
compared to negative $26.0 million in the same period in the prior
year.
- Cash and cash equivalents as of July 31, 2023 was $127.7
million, down $49.0 million from January 31, 2023.
Recent Events
On June 30, 2023, we acquired Comsort, Inc. d/b/a MediFind
(“MediFind”) (the "MediFind Acquisition"), for total consideration
of approximately $9.0 million. Consideration transferred included
$4.1 million of cash, 150,786 shares of Phreesia common stock
valued at $4.7 million and liabilities of $0.1 million. We acquired
$0.2 million in cash in connection with the MediFind Acquisition,
and we have presented cash paid to acquire MediFind of $3.9 million
in the accompanying consolidated statement of cash flows for the
six months ended July 31, 2023. MediFind is a consumer-facing
healthcare product that helps patients—especially those with
serious, chronic and rare diseases—find better care faster. We
acquired MediFind to reinforce our commitment to patient-centered
care and expand our offerings to consumers.
On August 11, 2023, we acquired Access eForms, LLC ("Access"),
an innovative electronic forms management and automation provider
that helps hospitals across the country streamline workflows,
improve compliance and deliver a better patient experience, for
total consideration of $38.4 million. Consideration transferred
included $6.5 million of cash, 1,096,436 shares of Phreesia common
stock valued at $30.6 million and liabilities of $1.2 million. We
acquired Access to enhance and build on our existing functionality
in the acute care space and to expand our network of clients and
partners.
Fiscal Year 2024 Outlook
We are maintaining our revenue outlook for the full fiscal year
2024 ending January 31, 2024 at between $353 million and $356
million, implying year-over-year growth of 26% to 27%.
We are raising our Adjusted EBITDA outlook for fiscal year 2024
to a range of negative $54 million to negative $49 million from a
previous range of negative $60 million to negative $55 million. The
change reflects our strong performance in the second quarter.
We have not reconciled our Adjusted EBITDA outlook to GAAP Net
income (loss) because we do not provide an outlook for GAAP Net
income (loss) due to the uncertainty and potential variability of
Other (income) expense, net and (Benefit from) provision for income
taxes, which are reconciling items between Adjusted EBITDA and GAAP
Net income (loss). Because we cannot reasonably predict such items,
a reconciliation of the non-GAAP financial measure outlook to the
corresponding GAAP measure is not available without unreasonable
effort. We caution, however, that such items could have a
significant impact on the calculation of GAAP Net income (loss).
For further information regarding the non-GAAP financial measures
included in this press release, including a reconciliation of GAAP
to non-GAAP financial measures and an explanation of these
measures, please see “Non-GAAP financial measures” below.
Fiscal Year 2025 Target
We are maintaining our $500 million revenue target to be
achieved by annualizing our highest-revenue quarter in fiscal year
20251 and we continue to expect to reach profitability2 during
fiscal year 2025. We also believe our cash and cash equivalents,
along with cash generated in the normal course of business, can
support our path to our fiscal year 2025 targets.
We believe our platform and diverse revenue streams offer us
multiple paths for achieving our targets.
1 For our target revenue, "annualized" is defined as multiplying
the highest-revenue quarter in fiscal year 2025 by four. 2 For the
purposes of this statement, we define "profitability" in terms of
Adjusted EBITDA.
Available Information
We intend to use our Company website (including our Investor
Relations website) as well as our Facebook, Twitter, LinkedIn and
Instagram accounts as a means of disclosing material non-public
information and for complying with our disclosure obligations under
Regulation FD.
Forward Looking Statements
This press release includes express or implied statements that
are not historical facts and are considered forward-looking within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements generally relate to future
events or our future financial or operating performance and may
contain projections of our future results of operations or of our
financial information or state other forward-looking information.
These statements include, but are not limited to, statements
regarding: our future financial and operating performance,
including our revenue, Adjusted EBITDA and our ability to reach
profitability in fiscal year 2025; our ability to finance our plans
to achieve our 2025 targets with our current cash balance and cash
generated in the normal course of business; our outlook for fiscal
year 2024 (including with respect to Adjusted EBITDA) and fiscal
year 2025 targets; and our belief that our platform and revenue
streams offer us multiple paths for achieving our targets; the
expected results and benefits of our acquisitions, including our
most recent acquisitions of MediFind and Access eForms; and our
expectations regarding the expansion of our offerings and our
network of clients and partners. In some cases, you can identify
forward-looking statements by the following words: “may,” “will,”
“could,” “would,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “project,”
“potential,” “continue,” “ongoing,” or the negative of these terms
or other comparable terminology, although not all forward-looking
statements contain these words. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, these statements relate to future events or our future
operational or financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by these forward-looking statements. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control, including, without
limitation, risks associated with: our ability to effectively
manage our growth and meet our growth objectives; our focus on the
long-term and our investments in growth; the competitive
environment in which we operate; our ability to develop and release
new products and services; our ability to develop and release
successful enhancements, features and modifications to our existing
products and services; changes in market conditions and receptivity
to our products and services; our ability to maintain the security
and availability of our platform; changes in laws and regulations
applicable to our business model; our ability to make accurate
predictions about our industry and addressable market; the impact
of pandemics on our business and economic conditions; our ability
to attract, retain and cross-sell to healthcare services clients;
our ability to continue to operate effectively with a primarily
remote workforce and attract and retain key talent; our ability to
realize the intended benefits of our acquisitions and partnerships,
including our recent acquisitions of MediFind and Access eForms;
difficulties in integrating our acquisitions and investments; and
the recent high inflationary environment and other general, market,
political, economic and business conditions (including as a result
of the warfare and/or political and economic instability in Ukraine
or elsewhere). The forward-looking statements contained in this
press release are also subject to other risks and uncertainties,
including those listed or described in our filings with the
Securities and Exchange Commission (“SEC”), including in our Annual
Report on Form 10-K for the fiscal year ended January 31, 2023 and
in our Quarterly Report on Form 10-Q for the fiscal quarter ended
July 31, 2023 that will be filed with the SEC following this press
release. The forward-looking statements in this press release speak
only as of the date on which the statements are made. We undertake
no obligation to update, and expressly disclaim the obligation to
update, any forward-looking statements made in this press release
to reflect events or circumstances after the date of this press
release or to reflect new information or the occurrence of
unanticipated events, except as required by law.
This press release includes certain non-GAAP financial measures
as defined by SEC rules. We have provided a reconciliation of those
measures to the most directly comparable GAAP measures, with the
exception of our Adjusted EBITDA outlook for the reasons described
above.
Conference Call Information
We will hold a conference call on Wednesday September 6, 2023,
at 5:00 p.m. Eastern Time to review our fiscal 2024 second quarter
financial results. To participate in our live conference call and
webcast, please dial (888) 350-3437 (or (646) 960-0153 for
international participants) using conference code number 4000153 or
visit the “Events & Presentations” section of our Investor
Relations website at ir.phreesia.com. A replay of the call will be
available via webcast for on-demand listening shortly after the
completion of the call, at the same web link, and will remain
available for approximately 90 days.
ABOUT PHREESIA
Phreesia is a trusted leader in patient activation, giving
providers, health plans, life sciences companies and other
organizations tools to help patients take a more active role in
their care. Founded in 2005, Phreesia enabled more than 120 million
patient visits in 2022 – more than 1 in 10 visits across the U.S. –
scale that we believe allows us to make meaningful impact. Offering
patient-driven digital solutions for intake, outreach, education
and more, Phreesia enhances the patient experience, drives
efficiency and improves healthcare outcomes. To learn more, visit
phreesia.com.
Phreesia, Inc.
Consolidated Balance
Sheets
(in thousands, except share and
per share data)
July 31, 2023
January 31, 2023
(Unaudited)
Assets
Current:
Cash and cash equivalents
$
127,677
$
176,683
Settlement assets
25,158
22,599
Accounts receivable, net of allowance for
doubtful accounts of $770 and $1,053 as of July 31, 2023 and
January 31, 2023, respectively
53,913
51,394
Deferred contract acquisition costs
820
1,056
Prepaid expenses and other current
assets
11,662
10,709
Total current assets
219,230
262,441
Property and equipment, net of accumulated
depreciation and amortization of $68,044 and $59,847 as of July 31,
2023 and January 31, 2023, respectively
22,816
21,670
Capitalized internal-use software, net of
accumulated amortization of $41,552 and $37,236 as of July 31, 2023
and January 31, 2023, respectively
41,205
35,150
Operating lease right-of-use assets
227
569
Deferred contract acquisition costs
1,370
1,754
Intangible assets, net of accumulated
amortization of $3,256 and $2,549 as of July 31, 2023 and January
31, 2023, respectively
12,994
11,401
Deferred tax asset
—
81
Goodwill
40,611
33,736
Other assets
1,989
3,255
Total Assets
$
340,442
$
370,057
Liabilities and Stockholders’
Equity
Current:
Settlement obligations
$
25,158
$
22,599
Current portion of finance lease
liabilities and other debt
7,112
5,172
Current portion of operating lease
liabilities
416
934
Accounts payable
7,948
10,836
Accrued expenses
27,794
21,810
Deferred revenue
16,441
17,688
Total current liabilities
84,869
79,039
Long-term finance lease liabilities and
other debt
8,055
2,725
Operating lease liabilities,
non-current
216
349
Long-term deferred revenue
99
125
Long-term deferred tax liabilities
183
—
Total Liabilities
93,422
82,238
Commitments and contingencies
Stockholders’ Equity:
Common stock, $0.01 par value -
500,000,000 shares authorized as of both July 31, 2023 and January
31, 2023; 55,364,795 and 54,187,172 shares issued as of July 31,
2023 and January 31, 2023, respectively
554
542
Additional paid-in capital
971,120
926,957
Accumulated deficit
(680,382
)
(606,084
)
Treasury stock, at cost, 1,300,430 and
971,236 shares as of July 31, 2023 and January 31, 2023,
respectively
(44,272
)
(33,596
)
Total Stockholders’ Equity
247,020
287,819
Total Liabilities and Stockholders’
Equity
$
340,442
$
370,057
Phreesia, Inc.
Consolidated Statements of
Operations
(Unaudited)
(in thousands, except share and
per share data)
Three months ended July
31,
Six months ended July
31,
2023
2022
2023
2022
Revenue:
Subscription and related services
$
39,301
$
31,069
$
77,188
$
60,170
Payment processing fees
23,631
19,581
47,884
38,962
Network solutions
22,898
17,217
44,603
32,089
Total revenues
85,830
67,867
169,675
131,221
Expenses:
Cost of revenue (excluding depreciation
and amortization)
14,449
14,873
29,356
29,259
Payment processing expense
15,852
12,554
31,942
24,712
Sales and marketing
37,244
38,341
74,657
78,372
Research and development
27,471
22,542
53,940
43,177
General and administrative
20,988
20,073
40,865
40,928
Depreciation
4,244
4,220
8,748
8,498
Amortization
2,537
1,599
5,023
3,203
Total expenses
122,785
114,202
244,531
228,149
Operating loss
(36,955
)
(46,335
)
(74,856
)
(96,928
)
Other income, net
50
38
8
7
Interest income (expense), net
786
(206
)
1,504
(589
)
Total other income (expense),
net
836
(168
)
1,512
(582
)
Loss before provision for income
taxes
(36,119
)
(46,503
)
(73,344
)
(97,510
)
Provision for income taxes
(648
)
(213
)
(954
)
(448
)
Net loss
$
(36,767
)
$
(46,716
)
$
(74,298
)
$
(97,958
)
Net loss per share attributable to
common stockholders, basic and diluted(1)
$
(0.68
)
$
(0.89
)
$
(1.39
)
$
(1.88
)
Weighted-average common shares
outstanding, basic and diluted
53,794,060
52,325,209
53,574,584
52,135,250
(1) Our potential dilutive securities have
been excluded from the computation of diluted net loss per share as
the effect would be to reduce the net loss per share. Therefore,
the weighted-average number of common shares outstanding used to
calculate both basic and diluted net loss per share attributable to
common stockholders is the same.
Phreesia, Inc.
Consolidated Statements of
Cash Flows
(Unaudited)
(in thousands)
Six months ended July
31,
2023
2022
Operating activities:
Net loss
$
(74,298
)
$
(97,958
)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization
13,771
11,701
Stock-based compensation expense
35,786
28,709
Amortization of deferred financing costs
and debt discount
169
144
Cost of Phreesia hardware purchased by
customers
650
546
Deferred contract acquisition costs
amortization
620
905
Non-cash operating lease expense
342
1,022
Deferred taxes
142
440
Changes in operating assets and
liabilities:
Accounts receivable
(2,370
)
(6,696
)
Prepaid expenses and other assets
769
3,190
Deferred contract acquisition costs
—
(177
)
Accounts payable
(2,415
)
3,715
Accrued expenses and other liabilities
6,061
983
Lease liabilities
(652
)
(647
)
Deferred revenue
(1,565
)
647
Net cash used in operating
activities
(22,990
)
(53,476
)
Investing activities:
Acquisitions, net of cash acquired
(3,873
)
—
Capitalized internal-use software
(9,820
)
(10,242
)
Purchases of property and equipment
(2,102
)
(2,634
)
Net cash used in investing
activities
(15,795
)
(12,876
)
Financing activities:
Proceeds from issuance of common stock
upon exercise of stock options
675
1,141
Treasury stock to satisfy tax withholdings
on stock compensation awards
(10,725
)
(6,309
)
Proceeds from employee stock purchase
plan
1,863
1,949
Finance lease payments
(3,427
)
(2,899
)
Constructive financing
1,688
—
Principal payments on financing
agreements
(45
)
(216
)
Debt issuance costs and loan facility fee
payments
(250
)
(397
)
Net cash used in financing
activities
(10,221
)
(6,731
)
Net decrease in cash and cash
equivalents
(49,006
)
(73,083
)
Cash and cash equivalents – beginning
of period
176,683
313,812
Cash and cash equivalents – end of
period
$
127,677
$
240,729
Supplemental information of non-cash
investing and financing information:
Property and equipment acquisitions
through finance leases
$
7,067
$
526
Purchase of property and equipment and
capitalized software included in current liabilities
$
1,509
$
2,379
Capitalized stock-based compensation
$
714
$
695
Issuance of stock to settle liabilities
for stock-based compensation
$
7,221
$
8,814
Issuance of stock as consideration in
business combinations
$
4,676
$
—
Issuance of liabilities as consideration
in business combinations
$
91
$
—
Capitalized software acquired through
vendor financing
$
2,047
$
—
Cash paid for:
Interest
$
354
$
446
Non-GAAP financial measures
This press release and statements made during the
above-referenced webcast may include certain non-GAAP financial
measures as defined by SEC rules.
Adjusted EBITDA is a supplemental measure of our performance
that is not required by, or presented in accordance with, GAAP.
Adjusted EBITDA is not a measurement of our financial performance
under GAAP and should not be considered as an alternative to net
income or loss or any other performance measure derived in
accordance with GAAP, or as an alternative to cash flows from
operating activities as a measure of our liquidity. We define
Adjusted EBITDA as net income or loss before interest (income)
expense, net, provision for income taxes, depreciation and
amortization, and before stock-based compensation expense and other
income, net.
We have provided below a reconciliation of Adjusted EBITDA to
net loss, the most directly comparable GAAP financial measure. We
have presented Adjusted EBITDA in this press release and our
Quarterly Report on Form 10-Q to be filed after this press release
because it is a key measure used by our management and board of
directors to understand and evaluate our core operating performance
and trends, to prepare and approve our annual budget, and to
develop short and long-term operational plans. In particular, we
believe that the exclusion of the amounts eliminated in calculating
Adjusted EBITDA can provide a useful measure for period-to-period
comparisons of our core business. Accordingly, we believe that
Adjusted EBITDA provides useful information to investors and others
in understanding and evaluating our operating results in the same
manner as our management and board of directors. We have not
reconciled our Adjusted EBITDA outlook to GAAP Net income (loss)
because we do not provide an outlook for GAAP Net income (loss) due
to the uncertainty and potential variability of Other (income)
expense, net and (Benefit from) provision for income taxes, which
are reconciling items between Adjusted EBITDA and GAAP Net income
(loss). Because we cannot reasonably predict such items, a
reconciliation of the non-GAAP financial measure outlook to the
corresponding GAAP measure is not available without unreasonable
effort. We caution, however, that such items could have a
significant impact on the calculation of GAAP Net income
(loss).
Our use of Adjusted EBITDA has limitations as an analytical
tool, and you should not consider it in isolation or as a
substitute for analysis of our financial results as reported under
GAAP. Some of these limitations are as follows:
- Although depreciation and amortization expense are non-cash
charges, the assets being depreciated and amortized may have to be
replaced in the future, and Adjusted EBITDA does not reflect cash
capital expenditure requirements for such replacements or for new
capital expenditure requirements;
- Adjusted EBITDA does not reflect: (1) changes in, or cash
requirements for, our working capital needs; (2) the potentially
dilutive impact of non-cash stock-based compensation; (3) tax
payments that may represent a reduction in cash available to us; or
(4) interest (income) expense, net; and
- Other companies, including companies in our industry, may
calculate Adjusted EBITDA or similarly titled measures differently,
which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider
Adjusted EBITDA along with other GAAP-based financial performance
measures, including various cash flow metrics, net loss, and our
GAAP financial results. The following table presents a
reconciliation of Adjusted EBITDA to net loss for each of the
periods indicated:
Phreesia, Inc.
Adjusted EBITDA
(Unaudited)
Three months ended
July 31,
Six months ended
July 31,
(in thousands)
2023
2022
2023
2022
Net loss
$
(36,767
)
$
(46,716
)
$
(74,298
)
$
(97,958
)
Interest (income) expense, net
(786
)
206
(1,504
)
589
Provision for income taxes
648
213
954
448
Depreciation and amortization
6,781
5,819
13,771
11,701
Stock-based compensation expense
18,648
14,558
35,786
28,709
Other expense, net
(50
)
(38
)
(8
)
(7
)
Adjusted EBITDA
$
(11,526
)
$
(25,958
)
$
(25,299
)
$
(56,518
)
Phreesia, Inc.
Reconciliation of GAAP and
Adjusted Operating Expenses
(Unaudited)
Three months ended
July 31,
Six months ended
July 31,
(in thousands)
2023
2022
2023
2022
GAAP operating expenses
General and administrative
$
20,988
$
20,073
$
40,865
$
40,928
Sales and marketing
37,244
38,341
74,657
78,372
Research and development
27,471
22,542
53,940
43,177
Cost of revenue (excluding depreciation
and amortization)
14,449
14,873
29,356
29,259
$
100,152
$
95,829
$
198,818
$
191,736
Stock compensation included in GAAP
operating expenses
General and administrative
$
5,747
$
5,206
$
11,625
$
10,334
Sales and marketing
7,111
5,423
13,528
11,077
Research and development
4,563
2,967
8,441
5,528
Cost of revenue (excluding depreciation
and amortization)
1,227
962
2,192
1,770
$
18,648
$
14,558
$
35,786
$
28,709
Adjusted operating expenses
General and administrative
$
15,241
$
14,867
$
29,240
$
30,594
Sales and marketing
30,133
32,918
61,129
67,295
Research and development
22,908
19,575
45,499
37,649
Cost of revenue (excluding depreciation
and amortization)
13,222
13,911
27,164
27,489
$
81,504
$
81,271
$
163,032
$
163,027
Phreesia, Inc.
Key Metrics
(Unaudited)
Three months ended July
31,
Six months ended July
31,
2023
2022
2023
2022
Key Metrics:
Average number of healthcare services
clients ("AHSCs")
3,445
2,776
3,377
2,651
Healthcare services revenue per AHSC
$
18,268
$
18,248
$
37,036
$
37,397
Total revenue per AHSC
$
24,914
$
24,448
$
50,244
$
64,004
We remain focused on building secure and reliable products that
derive a strong return on investment for our clients and
implementing them with speed and ease. This strategy continues to
enable us to grow our network of healthcare services clients. The
investments we make to grow, strengthen and sustain our network of
healthcare services clients lead to growth in all of our revenue
categories.
The definitions of our key metrics are presented below.
- AHSCs. We define AHSCs as the average number of clients that
generate subscription and related services or payment processing
revenue each month during the applicable period. In cases where we
act as a subcontractor providing white-label services to our
partner's clients, we treat the contractual relationship as a
single healthcare services client. We believe growth in AHSCs is a
key indicator of the performance of our business and depends, in
part, on our ability to successfully develop and market our
Platform to healthcare services organizations that are not yet
clients. While growth in AHSCs is an important indicator of
expected revenue growth, it also informs our management of the
areas of our business that will require further investment to
support expected future AHSC growth. For example, as AHSCs
increase, we may need to add to our customer support team and
invest to maintain effectiveness and performance of our Platform
and software for our healthcare services clients and their
patients.
- Healthcare services revenue per AHSC. We define Healthcare
services revenue as the sum of subscription and related services
revenue and payment processing revenue. We define Healthcare
services revenue per AHSC as Healthcare services revenue in a given
period divided by AHSCs during that same period. We are focused on
continually delivering value to our healthcare services clients and
believe that our ability to increase Healthcare services revenue
per AHSC is an indicator of the long-term value of the Phreesia
platform.
- Total revenue per AHSC. We define Total revenue per AHSC as
Total revenue in a given period divided by AHSCs during that same
period. Our healthcare services clients directly generate
subscription and related services and payment processing revenue.
Additionally, our relationships with healthcare services clients
who subscribe to the Phreesia Platform give us the opportunity to
engage with life sciences companies, health plans and other payer
organizations, patient advocacy, public interest and other
not-for-profit organizations who deliver direct communication to
patients through our Platform. As a result, we believe that our
ability to increase Total revenue per AHSC is an indicator of the
long-term value of the Phreesia Platform.
Additional Information
(Unaudited)
Three months ended July
31,
Six months ended July
31,
2023
2022
2023
2022
Patient payment volume (in millions)
$
989
$
811
$
2,005
$
1,648
Payment facilitator volume percentage
82
%
80
%
82
%
80
%
- Patient payment volume. We believe that patient payment volume
is an indicator of both the underlying health of our healthcare
services clients’ businesses and the continuing shift of healthcare
costs to patients. We measure patient payment volume as the total
dollar volume of transactions between our healthcare services
clients and their patients utilizing our payment platform,
including via credit and debit cards that we process as a payment
facilitator as well as cash and check payments and credit and debit
transactions for which we act as a gateway to other payment
processors.
- Payment facilitator volume percentage. We define payment
facilitator volume percentage as the volume of credit and debit
card patient payment volume that we process as a payment
facilitator as a percentage of total patient payment volume.
Payment facilitator volume is a major driver of our payment
processing revenue. Our payment facilitator volume percentage could
decline slightly over time should we increase our penetration of
enterprise customers that are less likely to use Phreesia as a
payment facilitator.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906148801/en/
Investor Contact: Balaji Gandhi Phreesia, Inc.
investors@phreesia.com (929) 506-4950 Media Contact: Maureen
McKinney Phreesia, Inc. mmckinney@phreesia.com (773) 330-8908
Phreesia (NYSE:PHR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Phreesia (NYSE:PHR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024